<DOC>
	<DOCNO>NCT03020082</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety Ritonavir-boosted ASC08 ( Danoprevir ) Combination Peg-IFN RBV Treatment-Naive Non-Cirrhotic Patients Who Have Chronic Hepatitis Genotype 1 .</brief_summary>
	<brief_title>Efficacy Safety Danoprevir/r + PR 12week Triple Therapy Treatment Naive Non-Cirrhotic G1 CHC China III</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Lactams</mesh_term>
	<criteria>Willing able provide write informed consent Chronic HCV infection ( ≥ 6 month ) Serum HCV RNA ≥ 1 × 104 IU/mL document Hepatitis C virus GT1 Never receive priortreatment HCV interferon , RBV , directacting hosttargeting antiviral HCV Noncirrhosis patient : Noncirrhosis define ( 1 ) Fibroscan define : ˂ 14.6 kPa screening period , liver biopsy determine 1 year recruiting ( Metavir score ˂ 3 ) ; ( 2 ) screening period 9.6 &lt; Fibroscan indicator ≤12.9 , liver biopsy need confirm noncirrhosis . Others specify detailed protocol Patients Fibroscan detection value &gt; 12.9 kPa , histologic examination liver cirrhosis patient Presence history nonhepatitis C chronic liver disease ( e.g . HH , AIH , Wilson 's disease , α1 antitrypsin deficiency , drug toxininduced liver disease ) History liver cell cancer , suspect hepatocellular carcinoma ( HCC ) patient screen , image study find suspicious nodule , AFP &gt; 50 ng/mL Positive hepatitis A antibody，positive hepatitis B surface antigen，HIV antibody Presence history nervous system diseases and/or mental illness , inability control oneself express oneself . Patients obvious cardiovascular dysfunction Pregnant nursing female , unwilling take reliable contraception Others specify detailed protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Danoprevir</keyword>
	<keyword>non-cirrhotic</keyword>
	<keyword>Chinese HCV G1</keyword>
	<keyword>SVR12</keyword>
</DOC>